Investing.com – U.S. stocks were higher after the close on Thursday, as gains in the Oil & Gas, Telecoms and Technology sectors led shares higher. At the close in NYSE, the Dow...
Axsome Therapeutics (NASDAQ:AXSM) +20% on raising $23.3M (NYSE:MMM) under existing ATM facility.Pyxis Tankers (NASDAQ:PXS) +13%.Taoping (NASDAQ:TAOP) +11% to acquire 51% of...
Investing.com – U.S. stocks were higher after the close on Monday, as gains in the Consumer Services, Oil & Gas and Telecoms sectors led shares higher. At the close in NYSE, the...
We expect GW Pharmaceuticals plc (NASDAQ:GWPH) to surpass expectations when it reports second-quarter 2019 results on Aug 6, 2019, after the market closes.Shares of GW...
CannTrust Holdings Inc. (NYSE:CTST) will report second-quarter 2019 earnings results.On Feb 25, 2019, the company started trading on the New York Stock Exchange (NYSE) under the...
La Jolla Pharmaceutical Company (NASDAQ:LJPC) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Sell||Sell||Sell||Strong Sell||Sell|
|Technical Indicators||Strong Sell||BUY||Strong Buy||Strong Sell||Strong Sell|
|Summary||Strong Sell||Neutral||Neutral||Strong Sell||Strong Sell|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Bullish doji Star||1D||2||Oct 10, 2019|
|Falling Three Methods||1W||3||Sep 22, 2019|
|Bullish Engulfing||1M||4||Jun 19|
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH). It has initiated a Phase III trial of LJPC-501 for the treatment of CRH, called the Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS) Phase III trial. LJPC-401 is its formulation of synthetic human hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is its next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections, as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.Read More
|Securities Investor Protection Corporation (United States)||$0||Start Trading|
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.